Skin and Connective Tissue Diseases
Skin and connective tissue disorders are a group of diseases that affect the skin, muscles, bones, blood vessels and other connecting tissues. These diseases may be caused by genetics, immune abnormalities, environmental factors, or other unknown factors. Some common skin and connective tissue diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), dermatomyositis, dry syndrome (SS), and systemic sclerosis.
In recent years, progress is being made in drug development for skin and connective tissue diseases, some of which are listed below:
- Janus kinase (JAK) inhibitors: JAK inhibitors are novel drugs for the treatment of skin diseases such as psoriasis and atopic dermatitis that work by modulating cell signaling.
- Aromatic hydrocarbon receptor (AhR) modulators: AhR is a transcriptional regulator involved in a variety of physiological processes, including immune regulation.AhR modulators have a unique mechanism of action for the treatment of inflammatory dermatoses and are emerging as a game changer in the landscape of dermatology.
- siRNA transdermal drug delivery system: siRNA (small interfering RNA) transdermal drug delivery system has become a hotspot in the research of skin disease treatment, especially siRNA inhibitors targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) can be used in the treatment of skin melanoma.
Skin and Connective Tissue Diseases Drug Targets
Skin and Connective Tissue Diseases Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/ml can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC50 is 3.243-7.085 ng/mL
-AC1.jpg)
Measured by its binding ability in a functional ELISA. Immobilized Human IL17A at 2 μg/ml can bind Anti-IL17A recombinant antibody (CSB-RA624104MA1HU), the EC50 is 1.818-2.170 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized Human IL4 (CSB-MP011659HU) at 2μg/mL can bind biotinylated Human IL4R，the EC50 is 12.68-14.23 ng/mL.
Measured in cell activity assay using U937 cells, the EC50 for this effect is 190.2-298.6 ng/ml.
